Search & Analyze

Suven Life Sciences Ltd.

HealthcarePharmaceuticals & Drugs

www.suven.com BSE: 530239NSE: SUVEN

₹334.85BSE0.16%

16 Sep, 4:01 PM

₹334.85

₹9.51K Cr

0.00

17.08

-101.80%

₹341.65

₹324.20

₹402.90

₹124.35

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Suven Life Sciences Ltd. SUVEN	334.85	0.00	9,509.65	0.00	-127.61	-147.70%	3.57	91.00%	-78.71

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2.39	1.01	2.57	1.61	1.47	1.87	0.92	2.81	1.52	3.57
Expenses	32.67	31.54	54.78	40.82	45.29	52.62	80.69	106.16	52.15	136.07
	-30.29	-30.54	-52.21	-39.21	-43.82	-50.75	-79.77	-103.35	-50.63	-132.50
	-1,269.94%	-3,035.69%	-2,029.07%	-2,435.09%	-2,987.05%	-2,718.16%	-8,680.20%	-3,679.25%	-3,331.12%	-3,715.73%
	4.28	4.01	4.04	1.63	1.22	0.60	3.78	2.77	6.78	7.52
Interest	0.03	0.02	0.02	0.01	0.00	0.00	0.00	0.00	0.16	0.48
	1.51	1.49	1.46	1.53	1.35	1.37	1.32	1.35	1.58	2.16
	-27.54	-28.04	-49.64	-39.12	-43.94	-51.52	-77.31	-101.92	-45.60	-127.61
	3.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	-26.54	-28.04	-49.64	-39.12	-43.95	-51.52	-77.31	-101.92	-45.60	-127.61
	-1.22	-1.29	-2.28	-1.79	-2.02	-2.36	-3.40	-4.48	-1.73	-4.83

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	11.84	13.54	11.69	6.66	7.11
	11.84	13.54	11.69	6.66	7.11
EXPENDITURE :
Power & Fuel Cost			0.26	0.30	0.56
Employee Cost	21.02	18.62	18.99	20.82	24.15
Other Manufacturing Expenses	106.53	115.72	115.15	145.00	249.18
General and Administration Expenses	6.09	4.63	5.09	5.96	17.34
Miscellaneous Expenses	0.46	0.33	0.08	0.23	0.24
	134.09	139.30	139.56	172.31	291.47
Operating Profit (Excl OI)	-122.25	-125.76	-127.86	-165.65	-284.36
	1.60	8.45	21.13	10.90	13.93
	-120.65	-117.31	-106.73	-154.76	-270.43
Interest	0.67	0.41	0.30	0.17	0.31
PBDT	-121.32	-117.72	-107.03	-154.92	-270.73
	4.39	6.54	6.50	5.82	5.61
Profit Before Taxation & Exceptional Items	-125.71	-124.27	-113.54	-160.75	-276.34
Exceptional Income / Expenses	3.72	6.00	7.46
	-122.00	-118.27	-106.08	-160.75	-276.34
Provision for Tax			-1.00
	-122.00	-118.27	-105.08	-160.75	-276.34
Extra items				0.00	0.00
Consolidated Net Profit	-122.00	-118.27	-105.08	-160.75	-276.34
Profit Balance B/F	-94.51	-216.65	-334.73	-439.87	-600.67
Appropriations	-216.50	-334.92	-439.81	-600.61	-877.02
	-8.39	-5.42	-4.82	-7.37	-10.48
Adjusted EPS	-7.73	-5.42	-4.82	-7.37	-10.48

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	14.54	21.81	21.81	21.81	26.37
Share Warrants & Outstandings				1.27	157.22
Total Reserves	81.61	353.51	248.23	86.90	407.81
Reserve excluding Revaluation Reserve	81.61	353.51	248.23	86.90	407.81
Revaluation reserve		0.00
	96.15	375.32	270.04	109.99	591.40
Other Long Term Liabilities	1.57	0.58			12.14
Long Term Provisions	2.00	1.88	1.35	1.71	1.92
Total Non-Current Liabilities	3.57	2.46	1.35	1.71	14.06
Trade Payables	1.99	1.66	2.07	5.23	4.81
Other Current Liabilities	5.44	8.44	10.33	16.62	12.42
Short Term Provisions	94.78	94.92	1.12	1.64	1.52
Total Current Liabilities	102.21	105.03	13.52	23.49	18.75
Total Liabilities	201.93	482.81	284.90	135.18	624.21
Gross Block	83.40	87.88	78.24	112.72	129.72
Less: Accumulated Depreciation	45.83	50.67	50.03	53.06	56.73
Net Block	37.56	37.21	28.21	59.65	73.00
Capital Work in Progress	3.55			0.01	3.60
Long Term Investment		0.00
Long Term Loans & Advances	0.33	0.11	0.02	0.05	0.91
Other Non Current Assets		100.00
Total Non-Current Assets	41.44	137.32	28.23	59.71	77.51
Currents Investments	45.16	46.34	75.94	22.28	180.65
Inventories	0.02		0.71	0.24	0.10
Sundry Debtors	1.30	0.81	1.29	1.34	1.51
Cash and Bank	5.52	184.28	163.98	37.73	337.46
Other Current Assets	1.18	5.12	2.79	1.08	4.64
Short Term Loans and Advances	107.31	108.93	11.97	12.82	22.35
Total Current Assets	160.49	345.48	256.67	75.47	546.71
Net Current Assets (Including Current Investments)	58.28	240.46	243.16	51.99	527.96
Total Assets	201.93	482.81	284.90	135.18	624.21
Contingent Liabilities			4.28	6.17	6.17
Total Debt	0.48	0.00	0.00	0.00	0.00
	6.61	17.21	12.38	4.99	16.46
Adjusted Book Value	6.09	17.21	12.38	4.99	16.46

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	-122.00	-118.27	-106.08	-160.75	-276.34
Adjustment	-1.09	-8.09	-22.46	-4.03	-5.98
Changes In working Capital	-3.93	11.48	6.89	10.07	-18.33
Cash Flow after changes in Working Capital	-127.02	-114.88	-121.65	-154.71	-300.66
Cash Flow from Operating Activities	-127.54	-115.98	-115.47	-154.10	-301.41
Cash Flow from Investing Activities	-22.23	-247.81	94.44	154.95	-462.11
Cash Flow from Financing Activitie	145.69	395.54	-1.05	-0.76	756.78
Net Cash Inflow / Outflow	-4.07	31.75	-22.09	0.09	-6.75
Opening Cash & Cash Equivalents	9.35	5.27	37.02	14.93	15.03
Closing Cash & Cash Equivalent	5.27	37.02	14.93	15.03	8.28

Ratios

Valuation

17.08

-26.56

1,078.93

-12.47

19.71

Profitability

-101.80

-78.71

-72.78

-3,996.73

-3,884.13

Leverage & Liquidity

0.00

29.15

-904.16

Returns

0.00

0.02

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	70.27	70.27	70.27	70.27	70.27	67.36	67.36	70.15	70.08
	1.50	1.39	1.39	0.26	0.61	4.57	4.46	5.53	3.50
	28.23	28.34	28.34	29.47	29.13	28.07	28.18	24.32	26.43
	29.73	29.73	29.73	29.73	29.73	32.64	32.64	29.85	29.92
No. of Shareholders	66,116	63,975	63,537	64,603	66,159	64,921	64,381	63,915	66,791

Corporate Actions

Showing: All

Date	Type	Details
2026-07-30	AGM
2026-07-30	Board Meeting	Quarterly Results
2026-05-06	Board Meeting	Audited Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Suven Life Sciences Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

7 members across the board and senior leadership

Venkateswarlu Jasti

Chairman & Managing Director

—

Seyed E Hasnain

Non Executive Independent Director

₹3.45 L

Mar '26

Santanu Mukherjee

Non Executive Independent Director

₹4.00 L

Mar '26

JAS Padmaja

Non Executive Independent Director

₹2.60 L

Mar '26

Vajja Sambasiva Rao

Non Executive Independent Director

₹4.25 L

Mar '26

Sangeetha Laxmi Kandari

Company Secretary & Compliance Officer

—

Sudha Rani Jasti

Whole Time Director

—

SUVEN Latest News

News

9 of 9 articles

EQUITY6 Aug 2026 · 15:42

Suven Life Sciences informs about board meeting

EQUITY14 Jul 2026 · 15:57

Suven Life Sciences informs about analyst meet

EQUITY10 Jul 2026 · 17:26

Suven Life Sciences informs about press release

EQUITY9 Jul 2026 · 11:21

Suven Life Sciences hits 52-week high after getting nod to incorporate subsidiary in Singapore

The new entity will be the Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics

COMPANY9 Jul 2026 · 11:14

Suven Life Sciences gets nod to incorporate subsidiary in Singapore

The new entity will be the Clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics

EQUITY16 Jun 2026 · 12:15

Suven Life Sciences informs about press release

EQUITY12 Jun 2026 · 12:01

Suven Life Sciences informs about news release

EQUITY4 Jun 2026 · 11:50

Suven Life Sciences informs about press release

EQUITY13 May 2026 · 14:01

Suven Life Sciences reports Profit after tax of Rs -111.67 Mln, in the March 2026 quarter

SUVEN

₹334.85

-0.16%